Prognostic Impact of Elective Supraclavicular Nodal Irradiation for Patients with N1 Breast Cancer after Lumpectomy and Anthracycline Plus Taxane-Based Chemotherapy (KROG 1418): A Multicenter Case-Controlled Study
- Author(s)
- Haeyoung Kim; Won Park; Jeong Il Yu; Doo Ho Choi; Seung Jae Huh; Yeon-Joo Kim; Eun Sook Lee; Keun Seok Lee; Han-Sung Kang; In Hae Park; Kyung Hwan Shin; Chan Woo Wee; Kyubo Kim; Kyung Ran Park; Yong Bae Kim; Sung Ja Ahn; Jong Hoon Lee; Jin Hee Kim; Mison Chun; Hyung-Sik Lee; Jung Soo Kim; Jihye Cha
- Keimyung Author(s)
- Kim, Jin Hee
- Department
- Dept. of Radiation Oncology (방사선종양학)
- Journal Title
- Cancer Research and Treatment
- Issued Date
- 2017
- Volume
- 49
- Issue
- 4
- Keyword
- Adjuvant radiotherapy; Breast neoplasms; Case-control studies; Lymphatic irradiation; Taxane
- Abstract
- PURPOSE:
This study was conducted to evaluate the impact of supraclavicular lymph node radiotherapy (SCNRT) on N1 breast cancer patients receiving post-lumpectomy whole-breast irradiation (WBI) and anthracycline plus taxane-based (AT) chemotherapy.
MATERIALS AND METHODS:
We performed a case-control analysis to compare the outcomes of WBI and WBI plus SCNRT (WBI+SCNRT). Among 1,147 patients with N1 breast cancer who received post-lumpectomy radiotherapy and AT-based chemotherapy in 12 hospitals, 542 were selected after propensity score matching. Patterns of failure, disease-free survival (DFS), distant metastasis-free survival (DMFS), and treatment-related toxicity were compared between groups.
RESULTS:
A total of 41 patients (7.6%) were found to have recurrence. Supraclavicular lymph node (SCN) failure was detected in three patients, two in WBI and one in WBI+SCNRT. All SCN failures were found simultaneously with distant metastasis. There was no significant difference in patterns of failure or survival between groups. The 5-year DFS and DMFS for patients with WBI and WBI+SCNRT were 94.4% versus 92.6% (p=0.50) and 95.1% versus 94.5% (p=0.99), respectively. The rates of lymphedema and radiation pneumonitis were significantly higher in the WBI+SCNRT than in the WBI.
CONCLUSION:
We did not find a benefit of SCNRT for N1 breast cancer patients receiving AT-based chemotherapy.
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.